Literature DB >> 17332921

Identification of DR9-restricted XAGE antigen on lung adenocarcinoma recognized by autologous CD4 T-cells.

Michihide Shimono1, Akiko Uenaka, Yuji Noguchi, Shuichiro Sato, Hideo Okumura, Kazuhiko Nakagawa, Katsuyuki Kiura, Mitsune Tanimoto, Eiichi Nakayama.   

Abstract

We previously demonstrated a dominant IgG response against XAGE-1b antigen in a lung cancer patient by serological analysis of antigens by recombinant expression cloning (SEREX) analysis using a cDNA library from the autologous OU-LU-6 tumor cell line. In this study, we investigated recognition of XAGE-1b on OU-LU-6 tumor by the patient CD4-expressing tumor-infiltrating lymphocytes (CD4 TIL). The response of CD4 TIL obtained from malignant pleural effusion was determined against autologous OU-LU-6 tumor cells and XAGE-1b mRNA-transfected PHA-stimulated CD4 T-cells (T-APC) from healthy individuals sharing HLA-DR with the patient by performing IFNgamma secretion and ELISPOT assays. The patient CD4 TIL recognized OU-LU-6 in an HLA-DR-restricted manner and XAGE-1b mRNA-transfected T-APC derived from DRB1 *0901-sharing healthy donor (HD)1 and HD2, but not DRB1 *1101-sharing HD3 or HD4. Epitope analysis using 17 18-mer peptides with 12 overlapping amino acids revealed that the CD4 TIL recognized XAGE-1b 33-49. The findings suggest that the patient CD4 T-cells recognized the XAGE-1b 33-49-related epitope on autologous OU-LU-6 tumor cells in a manner restricted by DR *0901.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17332921

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  9 in total

1.  mRNA expression of the XAGE-1 gene in human acute leukemia.

Authors:  Yuqiang Ji; Wanggang Zhang; Jin Wang; Liufang Gu
Journal:  Int J Hematol       Date:  2010-02-24       Impact factor: 2.490

Review 2.  Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.

Authors:  Pierre G Coulie; Benoît J Van den Eynde; Pierre van der Bruggen; Thierry Boon
Journal:  Nat Rev Cancer       Date:  2014-02       Impact factor: 60.716

3.  Hepatocellular carcinoma patients highly and specifically expressing XAGE-1 exhibit prolonged survival.

Authors:  Lei Gong; Jirun Peng; Zhuqingqing Cui; Pengcheng Chen; Hui Han; Dafang Zhang; Xisheng Leng
Journal:  Oncol Lett       Date:  2010-09-22       Impact factor: 2.967

4.  Prolonged survival of patients with lung adenocarcinoma expressing XAGE-1b and HLA class I antigens.

Authors:  Eiki Kikuchi; Koichi Yamazaki; Eiichi Nakayama; Shuichiro Sato; Akiko Uenaka; Noriyuki Yamada; Satoshi Oizumi; Hirotoshi Dosaka-Akita; Masaharu Nishimura
Journal:  Cancer Immun       Date:  2008-08-28

5.  Identification of the HERV-K gag antigen in prostate cancer by SEREX using autologous patient serum and its immunogenicity.

Authors:  Toshiaki Ishida; Yuichi Obata; Nobuya Ohara; Hirokazu Matsushita; Shuichiro Sato; Akiko Uenaka; Takashi Saika; Takako Miyamura; Kosuke Chayama; Yurika Nakamura; Hisashi Wada; Toshiharu Yamashita; Tsuneo Morishima; Lloyd J Old; Eiichi Nakayama
Journal:  Cancer Immun       Date:  2008-11-13

6.  [Association of XAGE-1 gene expression with clinical characteristics of lung cancer].

Authors:  Qun Lai; Litang Zhang; Yan Sun
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-08

Review 7.  Therapeutic Cancer Vaccines-Antigen Discovery and Adjuvant Delivery Platforms.

Authors:  Neftali Ortega Alarcon; Maddy Jaramillo; Heidi M Mansour; Bo Sun
Journal:  Pharmaceutics       Date:  2022-07-11       Impact factor: 6.525

8.  Immune Responses to the Cancer Testis Antigen XAGE-1b in Non Small Cell Lung Cancer Caucasian Patients.

Authors:  Kanako Saito; Eiichi Nakayama; Danila Valmori
Journal:  PLoS One       Date:  2016-03-03       Impact factor: 3.240

9.  Computational prediction of vaccine potential epitopes and 3-dimensional structure of XAGE-1b for non-small cell lung cancer immunotherapy.

Authors:  Mohammad M Tarek; Ayman E Shafei; Mahmoud A Ali; Mohamed M Mansour
Journal:  Biomed J       Date:  2018-05-21       Impact factor: 4.910

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.